Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Retained Earnings (2018 - 2025)

Historic Retained Earnings for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$330.0 million.

  • Whitehawk Therapeutics' Retained Earnings fell 496.18% to -$330.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$330.0 million, marking a year-over-year decrease of 496.18%. This contributed to the annual value of -$332.7 million for FY2024, which is 2368.02% down from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Retained Earnings is -$330.0 million, which was down 496.18% from -$312.3 million recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year Retained Earnings high stood at -$126.7 million for Q3 2021, and its period low was -$332.7 million during Q4 2024.
  • Its 5-year average for Retained Earnings is -$232.3 million, with a median of -$236.4 million in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first surged by 1066.97% in 2021, then plummeted by 4940.81% in 2022.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Retained Earnings stood at -$142.7 million in 2021, then crashed by 42.41% to -$203.2 million in 2022, then tumbled by 32.36% to -$269.0 million in 2023, then decreased by 23.68% to -$332.7 million in 2024, then rose by 0.8% to -$330.0 million in 2025.
  • Its Retained Earnings was -$330.0 million in Q3 2025, compared to -$312.3 million in Q2 2025 and -$259.6 million in Q1 2025.